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Background: Idiopathic renal hypouricemia (iRHUC) is an autosomal recessive hereditary disorder, characterized by
impaired tubular uric acid transport, re-absorption insufficiency and/or the acceleration of secretions. Some patients
present with severe complications, such as exercise-induced acute kidney injury (EIAKI) and nephrolithiasis.
Case presentation: Herein, we report the case of a girl with severe iRHUC (serum urate 0.05 mg/dL, fractional
excretion of uric acid 295.99%) associated with recurrent EIAKI, in whom the disease was caused by a homozygous
mutation (g.68G > A in exon 3) in the SLC2A9 gene. Her family members (father, mother and brother) carried the
same mutation but were heterozygous, without any signs of severe hypouricemia.
Conclusions: Our findings indicate that iRHUC is a rare disorder but that it should also be considered in patients
with EIAKI, especially in those patients who manifest with moderately elevated or normal serum concentrations of
uric acid during the acute phase of AKI. Mutational screening of the SLC2A9 gene is necessary for the diagnosis of
iRHUC, and homozygous mutations of the SLC2A9 alleles can cause severe hypouricemia. Careful attention should
be paid to any signs of hypouricemia during the recovery phase of AKI and long-term follow-up.
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Idiopathic renal hypouricemia (iRHUC) is an autosomal re-
cessive hereditary disorder characterized by impaired tubu-
lar uric acid (UA) transport, reabsorption insufficiency and/
or the acceleration of secretion [1-4]. Currently, there are
two subtypes of RHUC. Type 1 (RHUC1) is characterized
by loss-of function mutations in the SLC22A12 gene, which
encodes urate transporter 1 (URAT1). Mutations in the
SLC22A12 gene are responsible for most cases of renal
hypouricemia. In contrast, type 2 (RHUC2) was recently
revealed to be caused by defects in the SLC2A9 gene
[5]. Most of these patients are clinically asymptomatic
and are detected incidentally, but some have nephro-
lithiasis or hematuria or are predisposed to exercise-
induced acute kidney injury (EIAKI). Dinour et al.* Correspondence: maojh88@126.com
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unless otherwise stated.reported that homozygous mutations of SLC2A9 cause
more severe hypouricemia than URAT1 mutations and
are associated with a high incidence of renal calculus
and EIAKI [6].
The diagnosis of iRHUC is based on biochemical
markers: hypouricemia (<119 μmol/L or 2.0 mg/dL)
and increased fractional excretion of uric acid (FE-UA)
(>10%) [7]. Furthermore, the exclusion of secondary
causes of hyperuricosuric hypouricemia (such as Wilson’s
disease, Fanconi syndrome and drug-induced tubulopathy)
is very important. Confirmation of the diagnosis is accom-
plished by molecular analysis of the SCL22A12 and/or
SLC2A9 genes.
To present time [8], only more than 100 patients with
SLC22A12 mutations, and a few patients with SLC2A9
defects have been characterized worldwidely. Here, we
describe one case of idiopathic renal hypouricemia; the
patient presented with recurrent EIAKI and had a noveld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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An otherwise healthy 12.1-year-old girl presented to our
clinical department on October 22, 2010, with nausea,
vomiting and acute central abdominal pain for 4 days
after an 800-meter run. Her parents denied any illness,
viral prodrome or aminoglycoside or nonsteroidal anti-
inflammatory drug ingestion prior to exercising. Her urea
nitrogen is 32.62 mmol/L, creatinine 663.1 μmol/L (1 mg/
dl = 88.4 μmol/L) and uric acid 201.8 μmol/L (1 mg =
59.48 μmol/L). Thus, she was admitted to our ward with
acute kidney injury on October 25. Her past medical his-
tory was otherwise unremarkable. There was no family
history of muscle disorders or renal diseases.
On physical examination, her blood pressure was 139/
90 mmHg without orthostasis. Her weight and height
were 40 kg and 146 cm, respectively. The examination
was entirely unremarkable except for a mild lethargy.
There was no muscle swelling or tenderness.
The laboratory evaluation revealed the following results:
pH 7.443, potassium 4.7 mmol/L, bicarbonate 16.5 mmol/L,
SBE −6.8 mmol/L, creatine kinase 43 U/L (normal range
30–200 U/L), serum myoglobin 25.1 μg/L (normal range
0.1-70 μg/L), and blood β2-microglobulin 4233 ng/mL.
The urinalysis revealed a specific gravity of 1.020, a pH
of 5.5-5.0, 0–4 red blood cells/μL, rare renal tubular
epithelial cells and rare uric acid crystals. No glyco-
suria, aminoaciduria or crystallization was found. The
24-hour urinary protein and urine output were 604.3 mg
and 1500 mL, respectively. Her urinary secretory IgA was
1.13 μg/mL (normal range 0.74-2.5 μg/mL), a1-microglob-
ulin >32.8 mg/L (normal range 1.36-10.36 mg/L), microal-
bumin >50 μg/mL (normal range 3.03-16.81 μg/mL) and
immunoglobulin G 30 μg/mL (normal range 2.29-5.45
μg/mL). The following parameters were within normal
limits or negative: serum immunoglobulin; serum comple-
ment titer; antinuclear antibody (ANA); double-stranded
DNA (dsDNA); myeloperoxidase-antineutrophil cytoplas-
mic antibody (MPO-ANCA); perinuclear-antineutrophil
cytoplasmic antibody (P-ANCA); cytosolic-antineutrophil
cytoplasmic antibody (C-ANCA); PR3-ANCA; anti-
streptolysin O antibody (ASO); HIV; EBV; TORCH;
anti-glomerular basement membrane antibodies; HBsAg;
and hepatitis C antibody. Tests with pyrazinamide or pro-
benecid were not performed.
A renal biopsy was performed on day 9 after admission.
The light microscope revealed normal glomeruli and arteri-
oles, with vacuolar degeneration in the tubular epithelial
cells, accompanied by interstitial edema, scattered lympho-
cytes and monocyte infiltration. Immunofluorescence stain-
ings for IgG, IgA, IgM, C3, C4 and Fib were all negative.Electron microscopy showed focal effacement of foot pro-
cesses and a normal basement membrane without any
electron-dense deposits. These results revealed the kidney
to be recovering from acute tubular necrosis.
With conservative therapy of fluid control, her renal
function recovered gradually. After 15 days of admission,
she was discharged with improved renal function (BUN
10.52 mmol/L and serum creatinine 106.9 μmol/L). Dur-
ing the 1-year follow-up, her eGFR calculated by the
Schwartz formula [9] eventually recovered.
Second episode
Unfortunately, a relapse of EIAKI occurred nearly 1 year
after the first episode. On December 23, 2011, the pa-
tient was admitted again to our hospital with nausea,
vomiting, abdominal pain and loin pain after the same
exercise. The physical examination did not reveal any
abnormalities. Her blood pressure was 94/51 mmHg,
and her 24-hr urinary output was 1400 mL and 24-hr
urine protein excretion was 220 mg. In addition, Scr was
143 μmol/L, BUN was 12.59 mmol/L, and uric acid was
21 μmol/L. The serum copper ceruloplasmin was nor-
mal, and serum myoglobin was 21.3 μg/L. The 24-hour
urinary excretion of calcium and copper was within the
normal range. The renal ultrasound scan showed in-
creased echogenicity in the cortex of both kidneys, but
hydronephrosis was not observed. Her MRI was normal.
A second renal biopsy was conducted on December 28,
2011. Very slight mesangial cell proliferation and normal
arterioles were observed by light microscope, with moder-
ate vacuolar degeneration in the tubular epithelial cells,
accompanied by interstitial edema and small amounts of
lymphocytes and monocyte infiltration (Figure 1). Im-
munofluorescence stainings for IgG, IgA, IgM, C3, C4 and
Fib were all negative. The present renal tubular-interstitial
lesions appeared more moderate than previously.
This time, we noticed an extremely low concentration
of uric acid in the serum. We performed a fractional ex-
cretion of urate (FEUA), and the result was 295.99%. All
secondary causes of renal hypouricemia and EIAKI were
excluded. A diagnosis of EIAKI by idiopathic renal hypouri-
cemia was made retrospectively. After symptomatic treat-
ment, the patient was discharged on day 13. During the
follow-up, she was revealed to have normal Scr and eGFR,
but severe hypouricemia (3.1–8.7 μmol/L) remained. An-
aerobic activity was strictly prohibited, and no further epi-
sode of EIAKI occurred despite persistent hypouricemia at
the 1.5-year follow-up. The laboratory findings of Scr and
serum uric acid from each hospitalization are summarized
in Figure 2.
The serum UA level was also screened in other fam-
ily members. Her parents’ serum urate levels were
220.6 μmol/L (mother) and 263.4 μmol/L (father). Her
younger brother’s (8 years old) serum urate level was
Figure 1 Secondary renal biopsy revealed very slight mesangial cell proliferation and normal arterioles by light microscope, with
moderate vacuolar degeneration in the tubular epithelial cells (↖), accompanied by interstitial edema and small amounts of
lymphocytes and monocyte infiltration. A & B × 100, and C & D × 200.
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24.72%.
Mutational analysis
Secondary RHU, caused by isolated or generalized
tubular defects, such as Fanconi syndrome, Wilson dis-
ease, cystinosis, heavy metal poisoning or drug-inducedFigure 2 Variation of eGFR (ml/min) and serum uric acid (UA, μmol/L)
renal hypouricemia.tubulopathy, was excluded before the molecular analysis
of the SLC22A12 and SLC2A9 genes in the present study.
Sequence analysis of the SLC22A12 and SLC2A9 genes
was performed in the patient and her family members
under the diagnosis of EIAKI associated with idiopathic
renal hypouricemia. The clinical data collection and gen-
omic analysis was approved by the institutional ethicswithin 2.5-year follow-up in patient with idiopathic
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informed consent. No significant sequence variants in
SLC22A12 were found. The sequence analysis of the
SLC2A9 gene revealed a novel homozygous nonsense
mutation of g.68G > A in exon 3 (p.Trp23Stop), which
resulted in prematurely truncated GLUT9 protein in the
patient. No similar loss-of-function mutations have
been previously reported. A heterozygous mutation of
g.68G > A was also found in the parents and younger
brother (Figure 3). The results of the analysis in the pa-
tient’s family members suggested an autosomal recessive
mode of inheritance (Figure 4).Figure 4 Pedigree of the family carrying novel homozygous or
heterozygous mutation in SLC2A9 gene. The results of the
analysis in the patient’s family members suggested an autosomal
recessive mode of inheritance.Discussion
Hypouricemia is arbitrarily defined as a lower serum uric
acid (UA) concentration caused by decreased production
or increased excretion, and idiopathic renal hypourice-
mia (IRHU) is a familial hereditary disease characterized
by an increased renal urate clearance caused by an iso-
lated inborn error of membrane transport for urate in
the proximal renal tubules. Although most patients with
IRHU have no clinical symptoms or complications, the
major complications in this disease are urolithiasis and
exercise-induced acute kidney injury (EIAKI).
EIAKI associated with IRHU was first reported in 1989
by Erley et al. [10], and a number of cases have been re-
ported to date [8]. However, why renal hypouricemia
causes exercise-induced AKI remains unclear. One possi-
bility is that AKI might develop due to acute uric acidFigure 3 Electropherograms of partial sequences of exon 3 of SLC2A9
in patient exhibiting clinical features compatible with idiopathic rena
father, mother and brother.nephropathy, and tubular obstruction by uric acid has
been suggested as causing AKI [11]. Circulatory disturb-
ance of the kidney is an alternative mechanism, as most
renal biopsies in cases of exercise-induced AKI show no
uric acid crystallization. Because plasma uric acid is a
powerful antioxidant, anaerobic exercise induces an accu-
mulation of oxygen-free radicals, which are vasoconstrict-
ive, and this accumulation can result in a reduced
glomerular filtration rate. Uric acid seems to play ashowing a novel homozygous mutation g.68G > A (p.Trp23Stop)
l hypouricemia and same but heterozygous mutation in her
Shen et al. BMC Pediatrics 2014, 14:73 Page 5 of 7
http://www.biomedcentral.com/1471-2431/14/73protective role in the kidney, and the decreased antioxi-
dant potential in renal hypouricemia might lead to kid-
ney injury caused by ROS [12]. Furthermore, patient
with type I xanthinuria [13] presents very low serum
uric acid because of deficiency in xanthine dehydro-
genase, which catalyzes the oxidation of hypoxanthine
to xanthine and also of xanthine to uric acid. Affected
individuals pass multiple brownish-yellow stones and
surgical extraction would be required in some days.
Even though, probands with xanthinuria did not have
AKI in their medical history. It suggests [14], that
hypouricemia alone, probably, could not contribute to
renal injury in patients with primary renal hypourice-
mia. The powerful antioxidant activity of uric acid
might not be the fundamental factor for development
of AKI in patients with IRHU.
In the present study, no uric acid crystallization was
found in the tubular lumen of the kidney sample ob-
tained 9 and 5 days after the first and secondary onset,
respectively, of EIAKI. Thus, the role of a tubular ob-
struction by uric acid crystallization in EIAKI could be
excluded in the present case. Acute tubular necrosis,
induced by renal vasoconstriction and/or a reduced
glomerular filtration rate (because of volume depletion
after exercise and vomiting), might have played a role
in the pathogenesis of recurrent EIAKI in the present
case, according to the results of both renal biopsies.
Figure 3 presents the Scr and serum concentration of
uric acid simultaneously during the first and second
episodes of EIAKI and at follow-up.
SLC2A9 was first identified as a novel member of the
facilitative glucose transporter family in 2000 by Phay
et al. [15]. In 2008, Matsuo et al. [16] identified two
loss-of-function heterozygous mutations in SLC2A9 that
caused renal hypouricemia by decreased urate reabsorp-
tion on both sides of the proximal renal tubules. Since
then, several studies have reported on renal hypourice-
mia caused by SLC2A9 mutations (summarized in
Table 1). Among these studies, six patients were re-
ported as presenting with EIAKI. Dinour [6] reported
that three male Israeli-Arab patients with a homozygous
L75R mutation presented with EIAKI. Shima [17] re-
ported one female Japanese patient who presented with
EIAKI and PRES (posterior reversible encephalopathy
syndrome), caused by compound heterozygous G207X/
dupExon1a-11 mutations. Stiburkova [18] also reported
two renal hypouricemia patients presenting with EIAKI
caused by a homozygous G216R mutation or compound
heterozygous G216R/N333S mutations in the SLC2A9
gene. In the present study, the patient manifested with
EIAKI and carried a homozygous g.68G > A mutation;
her brother, mother and father did not present with
hypouricemia, elevated fractional excretion of uric acid
or EIAKI, although all three carried the same butheterozygous mutation. Above all, we conclude that
homozygous or compound heterozygous mutations in
the SLC2A9 gene are a prerequisite for presenting with
EIAKI in patients with renal hypouricemia. The same
phenomenon can also be observed in patients presenting
with EIAKI who have SLC22A12 mutations [19-21].
These results imply that not all mutations necessarily
lead to EIAKI and that the possible genotype-phenotype
correlation is complex and difficult to determine at the
present time. Furthermore, mutational analysis could be
a useful indicator for the clinical and prognostic evalu-
ation of patients with renal hypouricemia.
When a patient suffering from AKI with renal hy-
pouricemia is first seen, diagnosing renal hypourice-
mia is generally difficult because of the increased level
of UA [26] during the acute phase of the disease. In
the present study, the serum concentration of uric
acid was 201.8 μmol/L during the first episode of
EIAKI; thus, we did not realize that the EIAKI was
due to renal hypouricemia. After the second episode
of EIAKI, the repeated renal biopsy did not supply
any convincing evidence, and as we tried our best to
identify the cause of the AKI, we finally realized that
there might be a positive relationship in this patient
between hypouricemia and the two episodes of EIAKI.
Therefore, careful attention should be paid to any
signs of hypouricemia during the recovery phase of
AKI, especially in patients with recurrent AKI. If any-
one can realize the correlation between renal hypouri-
cemia and AKI at an appropriate timing, unnecessary
renal biopsies must have been avoided in such kind of
patients.
Recently, Bhasin et al. reported [27] an 18-year-old
white was diagnosed as iRHUC with recurrent AKI
after participating in 400-meter race. Before his next
race, he was prescribed allopurinol 300 mg daily for
3 days. He completed this race uneventfully. The
underlying mechanism for use of allopurinol is to de-
crease the production of uric acid, then, reducing the
filtered uric acid load and lessening the risk of precipi-
tation of the uric acid in the tubules of kidney. Thus,
the value of allopurinol to reduce the risk of exercise
induced AKI in patients with iRHUC deserves further
study.
Conclusions
Above all, iRHUC is a rare disorder, but it should be
considered in patients with EIAKI, especially in those
patients who manifest moderately elevated or normal
serum concentrations of uric acid during the acute
phase of AKI. Mutational screening of the SLC2A9
gene is necessary for the diagnosis of iRHUC, and
homozygous mutations of the SLC2A9 alleles can cause
severe hypouricemia. Careful attention should be paid
Table 1 Case reports of patients with renal hypouricemia caused by SLC2A9 mutations
Case reports Age (Year) Sex Mutation Ethnic group Serum urate
(mg/dL)
FEUA (%) Complications
Matsuo [16] 2008 70 F p.Arg380Trp* Japanese 1.5 15.7 No
43 M p.Arg380Trp* Japanese 2.7 14.6 No
32 F p.Arg198Cys* Japanese 2.1 — No
Anzai [22] 2008 36 F p.Pro412Arg * Japanese 2.4 — No
Dinour [6] 2010 46 M p.Leu75Arg# Israeli-Arab 0.2 >150 EIAKI
67 M p.Leu75Arg# Israeli-Arab 0.67 >150 Nephrolithiasis and CKD
36 M p.Leu75Arg# Israeli-Arab 0.04 >150 Nephrolithiasis
24 M p.Leu75Arg# Israeli-Arab 0.20 >150 EIAKI
19 M p.Leu75Arg# Israeli-Arab 0.10 >150 EIAKI
10 F p.Leu75Arg# Israeli-Arab 0.01 >150 No
69 M p.delExon7# Ashkenazi-Jewish 0.10 >150 Nephrolithiasis
Stiburkova [7,23] 2011 21 M p.insCExon3# Czech 0.17 220 No
16 F p.insCExon3# Czech 0.17 ± 0.05 194 ± 99 No
Shima [17] 2011 11 F p.Gly207X/p.dupExon1a-11*# Japanese 0.1 58.3 EIAKI
Dinour [24] 2012 7.5 F p. Arg171Cys# Israeli-Arab 0.1 138 No
5.5 M p. Arg171Cys# Israeli-Arab 0.1 157 No
2.3 F p. Arg171Cys# Israeli-Arab 0.2 88.8 No
84 M p.Thr125Met# Sephardi-Jewish 0.2 151 No
Stiburkova [18] 2012 12 M p.Gly216Arg # Anglo-Saxon 0.20 45.8 EIAKI
14 M p.Gly216Arg / p.ASN333Ser*# Anglo-Saxon 0.16 93 EIAKI
Current study 2013 12 F p.Trp23Stop# Chinese 0.05 295.99 EIAKI
8 M p.Trp23Stop/WT* Chinese 1.94 24.72 No
*Heterozygous, #Homozygous, *#Compound heterozygous. FEUA: fractional excretion of uric acid; EIAKI: exercise-induced acute kidney injury; CKD: chronic kidney
disease. Reference ranges for uric acid [4]: 2.0 ~ 5.7 for under 15 years and adult female, 2.0 ~ 7.0 for adult male. Reference ranges for FE-UA [4]: 7.3 ± 1.3 for under
15 years and adult female, 10.3 ± 4.2 for adult male. Mean/median value for serum creatinine [25]: 45 μmol/L for 1–3 year, 57 μmol/L for 4–8 year, and 66 μmol/L
for 9–17 year.
Shen et al. BMC Pediatrics 2014, 14:73 Page 6 of 7
http://www.biomedcentral.com/1471-2431/14/73to any signs of hypouricemia during the recovery phase
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Consent
Written informed consent was obtained from the pa-
tient’s legal guardian and from the patient for publica-
tion of this case report.
For classification according to the rate of decline of
glomerular filtration rate, CKD is staged as blow:
Stage 1: GFR ≥ 90 ml/min/1.73 m2
Stage 2: GFR 60 ~ 89 ml/min/1.73 m2
Stage 3a: GFR 45 ~ 59 ml/min/1.73 m2
Stage 3b: GFR 30 ~ 44 ml/min/1.73 m2
Stage 4: GFR 15 ~ 29 ml/min/1.73 m2
Stage 5: GFR < 15 ml/min/1.73 m2 or on dialysis
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